News
VLS underway replenishment (UNREP) has been a long-standing—and long-ignored-- vulnerability. Take this editorial snippet from a Fall 1988 issue of the long-unheralded UNREP Journal: ...
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMT VLS-01 is being ...
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. Phase Ib trial for sovilnesib, Volastra’s second KIF18A ...
“Dosing the first patient in the Phase 2 Elumina trial of VLS-01 marks a significant milestone in our commitment to transforming the treatment landscape for mental health disorders,” stated ...
About VLS-1488-2201 Trial (NCT05902988) The Phase 1/2 trial is evaluating the safety, tolerability, PK, and antitumor activity of VLS-1488 in patients with advanced solid tumors, ...
In a bid to improve the Mogami class's anti-submarine warfare (ASW) capabilities, Japan has begun installing the vertical launching system (VLS) on selected hulls of the ...
The UK Royal Navy (RN) has revealed plans to install the Lockheed Martin Mk 41 vertical launching system (VLS) into its five new Type 31 Inspiration-class general-purpose frigates.
atai Life Sciences. The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results